Researchers are testing sucrosomial iron, a new iron supplement designed to be better absorbed by the body, in 60 heart failure patients with iron deficiency through the RISE-HF trial. According to research reviewed by Gram, this special iron formulation bypasses the body’s natural absorption barriers that prevent regular iron pills from working effectively in heart failure patients. The trial will measure whether sucrosomial iron improves exercise capacity and quality of life over 24 weeks compared to placebo.
Researchers are testing a new type of iron supplement called sucrosomial iron to help people with heart failure who don’t have enough iron in their blood. Regular iron pills haven’t worked well for these patients because the body doesn’t absorb them properly. This new formulation is designed to get around the body’s natural absorption barriers. A Gram Research analysis of the RISE-HF trial shows scientists are enrolling 60 patients to see if this special iron supplement can improve how far people can walk and improve their quality of life over 24 weeks, compared to a placebo.
Key Statistics
The RISE-HF randomized controlled trial enrolls 60 patients with heart failure and iron deficiency to test whether sucrosomial iron improves exercise capacity and quality of life over 24 weeks, with results expected in 2027-2028.
Sucrosomial iron combines 30 mg of iron with 70 mg of vitamin C in a special formulation designed to partially bypass hepcidin-controlled absorption, addressing why conventional oral iron supplements have failed to improve outcomes in heart failure patients.
The trial uses a personalized dosing approach: patients with hemoglobin 10-13.9 g/dL receive 2 capsules daily, while those with hemoglobin 14-16 g/dL receive 1 capsule daily, to balance effectiveness with safety.
The Quick Take
- What they studied: Whether a new type of iron supplement called sucrosomial iron can help heart failure patients who have low iron levels exercise better and feel better overall.
- Who participated: 60 patients with heart failure and iron deficiency. Participants must have weakened heart pumping ability, low iron levels, and hemoglobin between 10-16 g/dL.
- Key finding: This is a study design paper, not results yet. Researchers will measure exercise capacity using a 6-minute walk test and quality of life using a standardized questionnaire at 12 and 24 weeks.
- What it means for you: If successful, this could offer heart failure patients an easier, cheaper way to treat iron deficiency without needing IV infusions. However, results won’t be available until the trial completes.
The Research Details
The RISE-HF trial is a randomized controlled trial, which is the gold standard for testing new treatments. Sixty patients with heart failure and iron deficiency will be randomly assigned to receive either sucrosomial iron (a special iron formulation with vitamin C) or a placebo (fake pill) for 24 weeks. Neither the patients nor the researchers will know who gets the real treatment until the study ends, which helps prevent bias.
The study uses a dose-adjustment approach based on each patient’s hemoglobin levels. Patients with lower hemoglobin (10-13.9 g/dL) take two capsules daily, while those with higher levels (14-16 g/dL) take one capsule. This personalized dosing helps balance effectiveness with safety.
Researchers will measure success using two main tests: a 6-minute walk test (how far patients can walk in six minutes) and a quality-of-life questionnaire. They’ll also check iron levels, heart function, and how well patients tolerate the supplement.
Regular oral iron supplements haven’t helped heart failure patients much because the body doesn’t absorb them well. Sucrosomial iron uses a special technology to bypass the body’s natural absorption barriers, potentially delivering more iron where it’s needed. This study design allows researchers to definitively prove whether this new approach actually works.
This is a well-designed study with several strengths: it’s randomized (reducing bias), double-blind (neither patients nor researchers know who gets the real treatment), placebo-controlled (allowing fair comparison), and uses objective measurements. The main limitation is the small sample size of 60 patients, which is why researchers plan a larger trial if results are promising. The study is registered with ClinicalTrials.gov, ensuring transparency.
What the Results Show
This paper describes the study design and rationale rather than actual results. The RISE-HF trial is currently enrolling patients and will measure two main outcomes at 12 weeks: exercise capacity (using the 6-minute walk test) and quality of life (using the Kansas City Cardiomyopathy Questionnaire-12). These measurements will be repeated at 24 weeks to see if benefits persist.
The study will also examine secondary outcomes including changes in iron status markers, oxidative stress biomarkers (which indicate cellular damage), and heart function measurements. Researchers will track how well patients tolerate the supplement, particularly any gastrointestinal side effects.
The rationale for this trial is based on a small case-control study showing sucrosomial iron had favorable effects. However, that earlier study was too small to prove effectiveness, which is why this larger randomized trial is necessary.
Beyond exercise and quality of life, researchers will measure iron status (transferrin saturation and ferritin levels), markers of oxidative stress, N-terminal pro type-B natriuretic peptide (a marker of heart stress), and echocardiographic measurements of heart function. These secondary measures will help explain how sucrosomial iron works and whether it affects the heart directly.
Conventional oral iron supplements have failed to improve outcomes in heart failure patients with iron deficiency, likely due to poor absorption. Intravenous iron works better but is expensive, requires healthcare visits, and carries risks of iron overload. Sucrosomial iron represents a middle ground: oral administration with potentially better absorption through a special delivery system that partially bypasses hepcidin (a hormone that controls iron absorption).
The main limitation is the small sample size of 60 patients, which limits statistical power to detect smaller effects. The 24-week duration may not be long enough to see all potential benefits. The study only includes patients with specific iron deficiency criteria, so results may not apply to all heart failure patients. Additionally, this is a single-center trial, so results may not generalize to different populations or healthcare settings.
The Bottom Line
This is a study design paper, not a completed trial, so no clinical recommendations can be made yet. However, heart failure patients with iron deficiency should discuss iron supplementation with their cardiologist. If this trial shows positive results, sucrosomial iron may become a recommended option. Current evidence supports treating iron deficiency in heart failure, but the best method remains uncertain.
Heart failure patients with documented iron deficiency should follow this research closely. Cardiologists and heart failure specialists will be particularly interested in the results. Patients currently taking regular iron supplements without benefit may especially benefit if this trial succeeds. However, people without heart failure or iron deficiency should not assume this applies to them.
The RISE-HF trial is currently enrolling patients. Results will likely be available in 2027-2028. Even if successful, it may take 1-2 additional years for regulatory approval and clinical adoption. Patients should not expect access to sucrosomial iron for heart failure until results are published and reviewed by regulatory agencies.
Frequently Asked Questions
What is sucrosomial iron and how is it different from regular iron supplements?
Sucrosomial iron uses a special delivery system that helps the body absorb iron better than regular iron pills. It partially bypasses hepcidin, a hormone that normally limits iron absorption. This allows more iron to reach the bloodstream, which is why it may work better for heart failure patients.
Can heart failure patients take regular iron supplements instead of waiting for sucrosomial iron?
Regular iron supplements haven’t improved outcomes in heart failure patients with iron deficiency, likely due to poor absorption. Intravenous iron works better but requires hospital visits and carries risks. Discuss with your cardiologist whether to wait for sucrosomial iron results or try other options.
How long will it take to see results if sucrosomial iron is approved?
The RISE-HF trial measures results at 12 and 24 weeks. If approved, patients might see improvements in exercise capacity and energy within 2-3 months. However, individual responses vary, and benefits may continue building over longer periods.
Who should not take sucrosomial iron for heart failure?
This trial only includes patients with specific iron deficiency criteria and hemoglobin levels between 10-16 g/dL. Heart failure patients without iron deficiency, those with iron overload, or those with hemoglobin outside this range should not take it without medical supervision.
What are the potential side effects of sucrosomial iron?
The RISE-HF trial will specifically measure gastrointestinal tolerability. Regular iron supplements commonly cause constipation, nausea, and stomach upset. Sucrosomial iron’s special formulation may reduce these side effects, but the trial will provide definitive safety data.
Want to Apply This Research?
- Track weekly 6-minute walk distance (how far you can walk in 6 minutes) and daily energy levels on a 1-10 scale to monitor exercise capacity improvements.
- If prescribed sucrosomial iron, set a daily reminder to take the supplement at the same time each day, and log any gastrointestinal symptoms to discuss with your doctor.
- Record monthly hemoglobin and iron levels from lab work, track exercise tolerance (stairs climbed, distance walked), and monitor quality of life using a simple weekly questionnaire about shortness of breath and fatigue.
This article describes a clinical trial design and does not report completed results. The RISE-HF trial is currently enrolling patients, and outcomes are not yet available. This information is for educational purposes only and should not replace medical advice from your cardiologist or healthcare provider. Do not start, stop, or change any heart failure medications or supplements without consulting your doctor. If you have heart failure and iron deficiency, discuss treatment options with your healthcare team.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.